PrintThe Burrill Report
The Burrill Report (July 22, 2013): Symplmed Sees Value in Being Direct (.MP3,22.08 Mb)
Symplmed, a spin out of the biotech Xoma, is trying to radically alter the business model for pharmaceutical companies. What makes the company compelling is not its products, but the way it’s selling them. Symplmed is using technology to change the way drugs are marketed and the way drugmakers interact with patients, providers, and payers. We spoke to Erik Emerson, president and CEO of Symplmed about the company’s approach, what’s wrong with the way drugs are sold today, and the opportunities for drugmakers to provide greater value than their medications alone.
July 18, 2013
http://www.burrillreport.com/article-symplmed_sees_value_in_being_direct.html
BUSINESS STRATEGY
Symplmed Sees Value in Being Direct
Podcast: July 22, 2013[Please login to post comments]
- Geisinger Allies with Genomics Researchers To Fight Liver Disease
Biopsy archive and sequencing power deliver results. Read More - Device Tax Foes Seize Opportunity in Budget Impasse
Bipartisan support exists for repeal, but only if it doesn't impede implementation of the Affordable Care Act. Read More - Big Data Comes to the Farm
Monsanto will pay $930 million for Climate Corp.’s weather-mining analytics and crop insurance services. Read More - Princess Di, Faked Moon Landings, and the Denial of Science
Study finds people who believe in conspiracy theories more likely to reject science. Read More - Intrexon Invests in Consumer-Focused “Living Art” Company
BioPop creates products using microorganisms for toys, novelty items, paintings. Read More - Wearable Health Tech Revenue Trends Toward $6B by 2018
Hot market is still fitness oriented, but lines are blurring as consumer demands evolve. Read More - Fate Therapeutics’ IPO Comes in Below Initial Target
Biotech slashes price, increases shares offered to raise $40.2M. Read More - Funding a Personalized Immunotherapy for MS
Podcast: October 7, 2013 Read More - What Winners Do to Beat the M&A; Odds
Podcast: October 2013 Read More - Lilly Still Plans on Meeting 2014 Goals
Company faces challenges, but is banking on new approvals and cost cutting. Read More
.gif)
